I went looking for why the dosing schedule is what it is and found that almost every practical question on this board has a pharmacokinetic answer nobody states.
The narrow version of the question is which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working.
Happy to be told the question itself is wrong.
Dr.ReproEndo said:I went looking for why the dosing schedule is what it is and found that almost every practical question on this board has a pharmacokinetic answer…
PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing. Semaglutide:
- Tmax: 24-72 hours post-injection
- T½: ~168 hours (7 days) — enables weekly dosing
- Steady state: reached at 4-5 weeks
- Bioavailability (SubQ): ~89%
- Volume of distribution: ~12.5L (primarily plasma)
The albumin binding (>99%) is the key pharmacological innovation — creating a sustained-release effect from a single injection. Previous GLP-1 agonists (exenatide) required BID dosing due to rapid clearance.
LipidDoc_ATL said:PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing.
LipidDoc_ATL has the substance of this right. The condition it depends on is worth stating. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.
Ask again with the specifics and you will get a better answer than this one.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsDr.ReproEndo said:I went looking for why the dosing schedule is what it is and found that almost every practical question on this board has a pharmacokinetic answer…
Adding a me-too, because a thread of one person's experience is not much use.
Adding the clinical framing, because it changes how the question reads.
Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest trajectory ever seen for an anti-obesity agent[1].
Amylin receptor agonism enhances satiety signaling through the area postrema and reduces glucagon secretion. Combined with GLP-1R agonism, this dual mechanism may produce even greater efficacy than current agents.
Early-stage data — interpret with caution. But the trajectory is extraordinary.
[1] Novo Nordisk investor presentation, September 2023.